Breast carcinomas and ovarian carcinomas {#Sec1}
========================================

In its guideline issued in May 2011, the Austrian Society for Gynecology and Obstetrics took a standpoint on prevention and early diagnosis of breast and ovarian cancers in high-risk patients. From this recommendation, the indication for molecular genetic analysis of *BRCA1* and *BRCA2* was defined \[[@CR1]\]:

**Indications for molecular genetic analysis of***BRCA1***and***BRCA2*

  --------------------------------------------------------------------------------------
  Two breast cancer cases before age of 50 years
  Three breast cancer cases before age of 60 years
  One breast cancer case before age of 35 years
  One breast cancer case before age of 50 years and one ovarian cancer case at any age
  Two ovarian cancer cases at any age
  Male and female breast cancer at any age
  --------------------------------------------------------------------------------------

This remains the basis for recommending genetic testing and meets the criteria for the cost to be paid by the Austrian national medical insurance system.

In Tyrol, Austria, the German S3 Guideline was incorporated into the recommendations of the Tyrolean Working Group for Clinical Oncology (TAKO) \[[@CR2]\].

**TAKO recommendations:**

**Only one affected person in a family**Breast cancer with first occurrence before age of 35 yearsBilateral breast cancer with first occurrence before age of 50 yearsBoth breast and ovarian cancer at any age**Multiple cases on the same side of a family**Two women with breast cancer, one with first occurrence before age of 50 yearsOne woman with breast cancer and one woman with ovarian cancerTwo women with ovarian cancerThree or more women with breast cancerOne man with breast cancer and one woman with breast or ovarian cancer

In general, a greater than 10 % prevalence of the mutation should be the threshold to recommend genetic testing. Even the very conservative National Institute for Health and Care Excellence recommends a genetic test at a calculated risk of 10 % or more \[[@CR3]\].

Until now, the costs for genetic testing in patients with an ovarian carcinoma have been covered only when the family history was positive, which meant that additional family members usually must have been diagnosed with ovarian and/or breast cancer. Recent findings, however, have shown that up to 15 % of patients with epithelial ovarian cancer have germline mutations in *BRCA1* or *BRCA2* \[[@CR4], [@CR5]\]. Half of these patients have no apparent family history for ovarian cancer. This may be due, on the one hand, to the absence of female relatives, and on the other hand, to the insufficient knowledge of the family medical history.

Germline mutations in *BRCA1* or *BRCA2* are associated with early-onset breast cancer. For ovarian cancer, the correlation with age is less clear, as 35 % of the patients with hereditary ovarian cancer are of the age of 60 + years at the time of diagnosis.

In addition to germline mutations, at least another 2--8 % of ovarian cancers have somatic *BRCA1* and *BRCA2* mutations \[[@CR5]\], so that up to 20 % of patients with ovarian cancer have a *BRCA1* or *BRCA2* deficiency triggered by a mutation. In addition, it is also known that 9--14 % of nonmutated ovarian cancers bear an epigenetic silencing of the *BRCA1* gene due to promoter hypermethylation \[[@CR6]\].

Identification of a *BRCA* mutation has many consequences. One of them is that patients with a mutation-induced BRCA dysfunction have better survival and respond better to platinum therapy. Furthermore, a BRCA germline mutation is also associated with a risk for other tumors, particularly breast cancer. Such patients can decide to undergo an intensive early detection program or prophylactic surgery. Identification of a germline mutation also provides important information for other family members and their potential tumor risk, and permits personalized preventive measures to be outlined for high-risk persons. Genetic testing has taken on special importance through the introduction of new therapeutic possibilities using so-called "PARP (Poly ADP ribose polymerase) inhibitors" that are particularly effective in the case of a *BRCA1* or *BRCA2* mutation \[[@CR7]\].

New technologies such as "next general sequencing" reduce the cost of genetic testing and permit additional genes to be tested. Blood samples taken in two GOG studies (GOG 218 and GOG 262) were subjected to genetic testing and showed a *BRCA1/2* mutation in 13.7 % of the patients with ovarian carcinoma, as well as mutations in other genes, in particular *BRIP1, PALB2, CHEK2, NBN,* and *ATM*, in 5.6 % of the patients \[[@CR8]\]. The new testing methods pose special challenges for interpretation of the genetic data, knowledge of a wide range of cancer predispositions, and genetic counseling.

On the basis of these new findings, the Association of Gynecologic Oncology (AGO) Austria makes the following recommendations for women with ovarian cancer:

Genetic testing for *BRCA1* or *BRCA2* germline mutations should be offered to all patients with an epithelial ovarian carcinoma. Patients with borderline ovarian tumors or nonepithelial ovarian tumors and who do not meet the criteria for hereditary breast and ovarian carcinoma cannot be expected to benefit from testing.Before germline mutation analysis of *BRCA1* and *BRCA2* in genomic DNA, the patient must undergo formal genetic counseling with regard to the possibility of a hereditary predisposition and must give her written consent for testing. The test results must be explained to the patient in a second personal genetic counselling session by a Medical Geneticist or a medical specialist for the particular indication as defined by the Austrian Gentechnikgesetz (GTG, Genetic Engineering Act). Counselling must be concluded with a counselling letter that contains all relevant points of the discussion, including the relevance of the findings for the patient's family.Before carrying out a genetic analysis of DNA isolated from tumor tissue that may potentially identify a germline mutation for example in *BRCA1* or *BRCA2*, the patient must be informed of the potential relevance of the test results for herself or other family members and must give her written consent for the test (for download see: AGO patient information sheet at: [www.ago-austria.at](http://www.ago-austria.at)).If a probable germline mutation is identified in the tumor tissue, the test results must be conveyed to the patient by genetic counseling in compliance with the Austrian GTG. The patient must be informed about the relevance of the test results for herself and other family members as well as the possibilities for further work-up, and she must be offered the opportunity for germline mutation testing in genomic DNA (typically isolated from blood).In view of the great significance for prognosis and treatment, especially, for possible PARP inhibitor therapy, not only a test for germline mutation, using DNA from a blood sample, but also quality-controlled testing of the tumor material should be performed. In an effort to personalize medicine, the AGO explicitly supports all innovative steps that promote the use of new technologies such as "next generation sequencing" to test for not only the two most common mutated genes, *BRCA1* and *BRCA2*, but also other genes involved in the homologous recombination repair of DNA as well as other relevant genes for ovarian cancer biology. In addition to testing solely for sequence alterations, assays should be developed in the future that also use, for example, epigenetic or functional analysis to better characterize tumor cells.
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